User:Harish Srinivas: Difference between revisions
From Proteopedia
Jump to navigationJump to search
No edit summary |
No edit summary |
||
| Line 63: | Line 63: | ||
[[Image:Nervous system'.jpg|thumb|1000px|centre|Fig7: Expression of S1PR and responses by neural cells. Neural progenitors express S1P1 and S1P2, neurons express S1P1 and S1P3, oligodendrocytes express S1P1 and S1P5, and astrocytes express S1P1 and S1P2. S1P1 couples exclusively to Gαi. S1P2 and S1P3 can couple to GαI, Gα12/13, or Gαq, and S1P5 can couple to GαI or Gα12/13(1).]] | [[Image:Nervous system'.jpg|thumb|1000px|centre|Fig7: Expression of S1PR and responses by neural cells. Neural progenitors express S1P1 and S1P2, neurons express S1P1 and S1P3, oligodendrocytes express S1P1 and S1P5, and astrocytes express S1P1 and S1P2. S1P1 couples exclusively to Gαi. S1P2 and S1P3 can couple to GαI, Gα12/13, or Gαq, and S1P5 can couple to GαI or Gα12/13(1).]] | ||
='''Therapeutic Target'''= | ='''Therapeutic Target & Applications'''= | ||
1.The first oral treatment for relapsing multiple sclerosis, the nonselective sphingosine-1-phosphate receptor (S1PR) modulator fingolimod, led to identification of a pivotal role of sphingosine-1-phosphate and one of its five known receptors, S1P1R, in regulation of lymphocyte trafficking in multiple sclerosis. clinical utility of S1P1R modulation for treatment of various immune mediated disorders(11). | 1.The first oral treatment for relapsing multiple sclerosis, the nonselective sphingosine-1-phosphate receptor (S1PR) modulator fingolimod, led to identification of a pivotal role of sphingosine-1-phosphate and one of its five known receptors, S1P1R, in regulation of lymphocyte trafficking in multiple sclerosis. clinical utility of S1P1R modulation for treatment of various immune mediated disorders(11). | ||
2.S1P1 is expressed in both hen and human ovarian tumors. S1P (the ligand for S1P1) has been implicated in the trafficking of immune cells. Immune cells are reported to be involved in the progression of tumors of various organs(10). | 2.S1P1 is expressed in both hen and human ovarian tumors. S1P (the ligand for S1P1) has been implicated in the trafficking of immune cells. Immune cells are reported to be involved in the progression of tumors of various organs(10). | ||
3.Development of a selective S1P1 receptor agonist, Syl930, as a potential therapeutic agent for autoimmune encephalitis(8). | |||
